. The presence of ANAs is a serological hallmark of systemic autoimmune rheumatic diseases, but their presence in sera from healthy people was also reported 2 . Anti-Dense Fine Speckled 70 (DFS70) antibodies, also known as lens epithelium-derived growth factor (LEDGF), were recently identified as associated to a specific ANA IIF pattern characterized by irregularly distributed, fine-granular fluorescence of the nuclei in the interphase and of the metaphase chromatin [3] [4] [5] [6] . Current knowledge of the DFS70/LEDGF autoantigen-autoantibody system identifies the antigen as a transcription co-activator able to upregulate some stress protective and inflammatory genes. This function could contribute to the cellular survival under environmental stress factors, both in health and in disease context 7, 8 . The alteration of DFS70 function or structure may trigger disease pathogenesis and autoantibody elicitation. The autoantibodies are preferentially of the IgG class and target a conserved region in DFS70 C-terminal domain. The prevalence of anti-DFS70 antibodies was analyzed in different cohorts with value ranged from 0.8% to 16.6% [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . These variations may be related to differences in the patient selection criteria and methodological aspects as different HEp-2 substrates, to inter-reader variability in pattern assignment and variation in screening dilution. Furthermore, in some studies, no confirmatory analyte-specific immunoassays were employed. Also, the agreements between DFS70 IIF suspicion and confirmation by specific assays varied widely among studies. The discrepancies were related to different antigen exposure and selection (full length LEDGF or selected antigenic region), analytical sensitivity/specificity and manufacturer's cut-off of the various confirmatory assays 23 . However, use of DFS70-specific immunoassays was recently suggested by a study showing a low accuracy in assessing the DFS70 IIF pattern by experienced technologists 24 .
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Methods
Samples. Collected 30 . Positive/negative interpretation based on a F.I. was evaluated during focusing and confirmed by expert-readers. Positive samples were also tested using the conventional serial dilution method (1:160, 1:320, 1:640, 1:1280 until to 1:2560) to assign end-point titer. The titer was defined as the reciprocal of the highest dilution of serum that still shows immunofluorescent staining.
Immunoblot Anti-DFS70 Assay. The serum samples positive for DFS70-like pattern in IIF were further processed for detection of human IgG autoantibodies against DFS70 specificity (truncated sequence of the DFS70 antigen (residues 349-435)) by Immunoblotting assay. In addition, confirmed anti-DFS70 positive samples, were also evaluated for the antibodies against Sm, U1-RNP, Sm/RNP, SSA/Ro60kD, SSB, Scl-70, PM-Scl 100, Ku, CENP-A/B, PCNA, Mi-2 antigens using immunoblotting kit (Alphadia, Wavre, Belgium) by automatic Blu Diver Instrument (BDI) (Alifax, Polverara (PD), Italy). During the automated test procedure, the BDI sequentially incubates the strips in the wells of ready-to use reagent cartridges. Human antibodies bind the corresponding specific antigen(s) on the membrane and enzyme activity leads to development of purple dots on the membrane pads. The intensity of the coloration is directly proportional to the amount of antibody present in the sample. Semi-quantitative interpretation was done by Dr Dot Software (Alifax) and scanning system using Arbitrary Unit (AU).
Detection of other autoantibodies. Anti-DFS70 positive samples were tested for the presence of other serum autoantibodies: anti-extractable nuclear antigen (ENA) (RNP/Sm, SSA/Ro, SSB/La, Scl-70, Jo-1, CENP-B), anti-thyroid peroxidase (TPO), anti-thyroglobulin (TGAb) and anti-tissue transglutaminase (tTg)-IgA by a fully automated chemiluminescence analyzer LIAISON XL (Diasorin, Saluggia (VC), Italy) using a 'Flash' chemiluminescence technology (CLIA) with paramagnetic microparticle solid phase; anti-dsDNA by the Crithidia luciliae IIF Test (Euroimmun, Padova (PD), Italy); IgG class of anti-mitochondrial (AMA), anti-smooth muscle (ASMA), anti-liver/kidney/microsome type 1 (LKM), and anti-parietal cells (PCA) by triple IIF test on rat liver, stomach and kidney substrates (Alphadia); anti-neutrophil cytoplasmic myeloperoxidase (MPO) and proteinase 3 (PR3) through enzyme immunoassay (GA GENERIC assays GmbH, Dahlewitz, Germany) performed on automatic Immunomat Serion ELISA analyzer (SERION Immunologics, Wurzburg, Germany) as recommended by the manufacturer; anti-Saccharomyces Cerevisiae IgG/IgA (ASCAs) and anti-cardiolipin/β2-GPI complex and β2-GPI isolated protein IgG (aCL) using immunodot kit, a previously described diagnostic assay platform.
Statistical analysis. Statistical analyses were performed using the Graph Pad Prism statistical package (v5; Graph Pad Software, San Diego, CA). Statistical significance was calculated using the non-parametric Mann-Whitney-U test and correlations were analyzed by the Spearman's rank correlation test and R-squared analyses (R 2 ); categorical variables were compared using Fisher' Test. A p value < 0.05 was considered statistically significant.
Ethics approval and consent to participate. The study was approved by the Regional Ethics Committee the typical DFS70 staining pattern. Titer distribution revealed no statistically differences when compared with other ANA patterns (p > 0.05). More than half of the patients presenting DFS70 monopattern (63% of the total cohort) showed high titers (≥1:640) (Fig. 3) . A quantitative comparison between DFS70 IIF titers and AU immunoblotting showed an excellent correlation between two methods as expressed by a Spearman correlation (Fig. 4A ). Regression analysis (R 2 = 0.99) also confirmed the relationship between IIF titers and immunoblotting AU (Fig. 4B) .
Association of anti-DFS70 and other serum autoantibodies. Collected DFS70-positive serum samples were assayed for a large spectrum of other circulating autoantibodies. By comparing DFS70-positive males with females, it emerged that isolated anti-DFS70 reactivity was found only in the male group. In contrast, in the 51% of DFS70-positive females, concomitant serum autoantibodies were found. Most common detected autoantibodies were anti-TPO (16.0%), anti-TG (11.0%), anti-tTg-IgA (9.0%) and ANCA (2.2% anti-PR3, 2.2% anti-MPO and 2.2% both). Only two subjects had both anti-TPO and anti-TG antibodies. ASCAs were detected only in one DFS70-positive female, also positive for anti-TPO, anti-TG and anti-tTg-IgA; anti-cardiolipin in two other and anti-ENA (anti-Mi-2 antibody) in one which also showed anti-TPO antibody positivity. No anti-DFS70 positive female, carried concomitant anti-dsDNA, anti-PCA, AMA, ASMA and anti-LKM was found (Fig. 5) .
Clinical phenotypes of anti-DFS70 positive patients. Clinical features of anti-DFS70 positive subjects were as follows: 37 healthy subjects (29 F, 8 M) and remaining (16 F, 2 M) suffered from various diseases. In the latter group 3 had spondyloarthritis (SpA), 1 morphea, 1 undifferentiated connective disease (UCTD), 3 rheumatoid arthritis (RA), 1 alopecia areata, 1 Crohn's disease, 4 celiac disease (CD), 1 autoimmune thyroiditis (AT), 1 RA-UCTD overlap syndrome, 1 CD plus AT, and 1 SpA plus AT. 
Discussion
Previous studies using ANA-IIF test on HEp-2 substrates provide the detection of high-titer autoantibodies with typical DFS70 staining pattern in 1% to 16% of the studied cohorts. These heterogeneous results were obtained in different patient cohorts, including blood donors, healthy individuals, routine ANA cohorts, selected ANA positive healthy individuals and routine ANA positive subjects [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . In details, a rate of positivity ranged from 0 to 5% was found in blood donors, healthy children and in routine ANA screening cohort. Higher frequencies were reported in ANA-positive populations. In addition, some studies examined serum samples only by IIF without specific confirmatory assays, resulting in higher rate of positivity. It has been showed that not all samples displaying DFS70 IIF pattern were then confirmed by specific CLIA or ELISA methods 23, 32, 33 . We analyzed 3175 consecutive unselected samples screened for ANA during the routine work-up by IIF at screening dilution of 1:160, then confirmed by immunoblotting (Fig. 1) . We found 1.7% of anti-DFS70 positive sera, in line with some previous studies conducted on routine ANA screening population 6, 10, 13, 16, 19, 21, 34 . In fact, Mahler et al. 6 analyzed 3263 sera submitted for ANA screening for the presence of anti-DFS70 antibodies and observed 1.62% of positivity. Noteworthy, Bizzaro et al. 15 also reported a low frequency (0.8%) of sera displaying the anti-DFS70 reactivity on HEp-2 substrate in a large cohort of samples screened for ANA in clinical laboratory. However, because our study was performed with ANA-requested specimens from outpatients and inpatients, the overall frequency of anti-DFS70 antibodies in general population is unknown. Gender differences with greater prevalence of female (4:1) was observed in anti-DFS70 negative/ANA positive group and within the anti-DFS70 positive samples. This is an important finding since the increased immune reactivity in females predisposes them to developing AARD. A number of factors may underlie this striking gender difference and further studies are needed to better understand these findings.
Regarding referring sources of anti-DFS70 positive samples, a comparative analysis highlighted that greater prevalence of anti-DFS70 positive subjects referred from the outpatients, with value of 2.1% (Fig. 2) .
We found high titers (≥1:640) in 64.3% of the DFS70 IIF-positive sera, with a titer greater than 1:2560 found only in one sample. Titer distribution revealed no statistically differences when compared with other ANA positivity (p > 0.05) (Fig. 3) .
The use of specific methods to confirm DFS70 IIF suspicion was highly recommended. Recent data showed that there were no differences in diagnostic accuracy among methods using truncated (as Alphadia Dot) or full-length DFS70 antigenic sequence 34, 35 . We perform a quantitative comparison among IIF titers and immunoblotting AU in anti-DFS70 positive sera resulting in excellent correlation (Fig. 4A,B) .
We also analyzed the simultaneous presence of a broad spectrum of other circulating disease-markers autoantibodies. Muro et al., found a high prevalence of disease-related autoantibodies in anti-DFS70 positive patients, but of note, their cohort included only 22 anti-DFS70 positive females. Noteworthy, our data evidenced isolated reactivity of anti-DFS70 autoantibodies in male group, and high prevalence of disease-marker autoantibodies in females (51%). In particular, most common detected autoantibodies were anti-TPO, anti-TG, anti-tTg-IgA and ANCA (Fig. 5) . It is hoped that future studies will compare the prevalence of concomitant antibodies in males versus females either in ANA positive/anti-DFS70 negative group.
Major strengths of our study are the use of anti-DFS70 confirmatory assay to avoid false positive results and the gender analysis in appraisal of the anti-DFS70 antibodies prevalence. The prevalence of anti-DFS70 was previously assessed in different cohorts mostly smaller than ours, therefore, we believe that our anti-DFS70 positive cohort should be considered suitable for a preliminary evaluation although a future larger confirmatory study is needed. In contrast, the scarce number of anti-DFS70 positive males could be considered inadequate to draw any firm conclusions. Therefore, based on low male prevalence, it is mandatory to screen larger cohort by future multicentre studies.
Conclusion
According to previous observations performed on routine ANA cohorts, our prevalence of anti-DFS70 positivity was 1.7% of adult screened population. Serological profile of anti-DFS70 positive females required further clinical and laboratory investigations in order to define the presence of associated disease-marker autoantibodies and their clinical significance. In contrast, isolated anti-DFS70 specificity in male population suggests that the DFS70 could be considered reliable screening indicator for absence of other circulating autoantibodies resulting in considerable cost-saving potential.
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